Navigation Links
Mentice AB Announces Leadership Changes Within Its Worldwide Operations
Date:3/11/2008

GOTHENBURG, Sweden, March 11 /PRNewswire/ -- Mentice AB, a leading supplier of virtual reality based training applications within the field of medicine has recently appointed James Ruscoe as Chairman of the Board and Goran Malmberg as President and CEO of Mentice.

Mr. Ruscoe graduated from Oxford University and brings with him a vast array of experience in innovative technologies. He also serves as CEO and board member of several Swiss private and charitable foundations. Mr. Ruscoe is the former advisor to the Presidency of the European Commission on the competitive implications of innovation; to the Chairman of the European Round Table of Industrialists, Brussels; and to the Chairman of the Italian National Agency for Innovation, New Technologies and the Environment, Rome.

Mr. Malmberg, formerly a member of the Mentice board, has extensive sales and marketing experience from executive positions within the software industry and has held sales management and senior executive roles with international focus during the last 15 years.

"I am excited about joining Mentice which I personally feel is an innovative and progressive company in a market with considerable potential. My goal is to develop the company through further product development while enhancing our sales and marketing operations. We trust the industry will notice the result of these changes in the very near future as Mentice works to maintain its leadership position by broadening its presence throughout the worldwide VR marketplace," said Goran Malmberg.

About Mentice:

Mentice is a leader in medical simulation with approximately 600 installations worldwide, 100 validation studies and more than 30 issued and pending patents. Mentice's Family of Procedicus (TM) simulators focus on the area of minimally invasive surgery within the fields of endovascular, cardiovascular and neurological intervention, core skills training, laparoscopy and arthroscopy.

Website info: http://www.mentice.com

Release #31008


'/>"/>
SOURCE Mentice Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
2. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
3. Lilly Announces Termination of AIR Insulin Program
4. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
5. Spectral announces 2007 financial results
6. Finesse Solutions, LLC Announces OPC Connectivity With Nova BioProfile 400
7. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
8. Senetek PLC Announces Appointments of Key Personnel
9. Iomai Announces Year-End 2007 Financial Results and Business Progress
10. Dragon announces new product launch; increase in annual production output capacity
11. Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , ... October 12, 2017 , ... ... today announced the three Winners and six Finalists of the 2017 Blavatnik Regional ... by the Blavatnik Family Foundation and administered by the New York Academy of ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... Rosalind™, the first-ever genomics analysis platform specifically designed for life science researchers ... honor of pioneering researcher Rosalind Franklin, who made a major contribution to ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... pathology, announced today it will be hosting a Webinar titled, “Pathology is going ... Pathology Associates , on digital pathology adoption best practices and how Proscia improves ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
Breaking Biology Technology:
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
Breaking Biology News(10 mins):